BCL2L1 and lung carcinoma: ABBV-637, an ADC consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to an inhibitor of BCL-XL, and ABBV-155, an ADC composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated to a BCL-XL inhibitor are now in Phase 1 clinical trials for lung cancer treatment62 (NCT04721015 and NCT03595059).